PortalPublikationenAnaemia in cancer patients: pathophysiology, incidence and t...

Anaemia in cancer patients: pathophysiology, incidence and treatment

Standard

Anaemia in cancer patients: pathophysiology, incidence and treatment. / Bokemeyer, C; Oechsle, K; Hartmann, J-T.

in: EUR J CLIN INVEST, Jahrgang 35 Suppl 3, 12.2005, S. 26-31.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bokemeyer, C, Oechsle, K & Hartmann, J-T 2005, 'Anaemia in cancer patients: pathophysiology, incidence and treatment', EUR J CLIN INVEST, Jg. 35 Suppl 3, S. 26-31. https://doi.org/10.1111/j.1365-2362.2005.01527.x

APA

Bokemeyer, C., Oechsle, K., & Hartmann, J-T. (2005). Anaemia in cancer patients: pathophysiology, incidence and treatment. EUR J CLIN INVEST, 35 Suppl 3, 26-31. https://doi.org/10.1111/j.1365-2362.2005.01527.x

Vancouver

Bokemeyer C, Oechsle K, Hartmann J-T. Anaemia in cancer patients: pathophysiology, incidence and treatment. EUR J CLIN INVEST. 2005 Dez;35 Suppl 3:26-31. https://doi.org/10.1111/j.1365-2362.2005.01527.x

Bibtex

@article{4d25f67e38ae4997bc48609bb02b2b5b,
title = "Anaemia in cancer patients: pathophysiology, incidence and treatment",
abstract = "This review focuses on the pathophysiology, incidence and treatment of anaemia in cancer patients. Causative factors such as different chemotherapy regimens and patient risk factors for the development of anaemia are discussed in order to identify the patient group that is most likely to receive red blood cell transfusions and would thus have the largest benefit from treatment with erythropoietic proteins. The data available with recombinant human erythropoietin alfa, recombinant human erythropoietin beta and darbepoetin alfa are described in more detail and the significant benefit of treating cancer anaemia by these molecules is outlined. Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation.",
keywords = "Anemia, Antineoplastic Agents, Drug Administration Schedule, Erythropoiesis, Erythropoietin, Hematinics, Humans, Neoplasms, Recombinant Proteins, Treatment Outcome",
author = "C Bokemeyer and K Oechsle and J-T Hartmann",
year = "2005",
month = dec,
doi = "10.1111/j.1365-2362.2005.01527.x",
language = "English",
volume = "35 Suppl 3",
pages = "26--31",
journal = "EUR J CLIN INVEST",
issn = "0014-2972",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Anaemia in cancer patients: pathophysiology, incidence and treatment

AU - Bokemeyer, C

AU - Oechsle, K

AU - Hartmann, J-T

PY - 2005/12

Y1 - 2005/12

N2 - This review focuses on the pathophysiology, incidence and treatment of anaemia in cancer patients. Causative factors such as different chemotherapy regimens and patient risk factors for the development of anaemia are discussed in order to identify the patient group that is most likely to receive red blood cell transfusions and would thus have the largest benefit from treatment with erythropoietic proteins. The data available with recombinant human erythropoietin alfa, recombinant human erythropoietin beta and darbepoetin alfa are described in more detail and the significant benefit of treating cancer anaemia by these molecules is outlined. Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation.

AB - This review focuses on the pathophysiology, incidence and treatment of anaemia in cancer patients. Causative factors such as different chemotherapy regimens and patient risk factors for the development of anaemia are discussed in order to identify the patient group that is most likely to receive red blood cell transfusions and would thus have the largest benefit from treatment with erythropoietic proteins. The data available with recombinant human erythropoietin alfa, recombinant human erythropoietin beta and darbepoetin alfa are described in more detail and the significant benefit of treating cancer anaemia by these molecules is outlined. Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation.

KW - Anemia

KW - Antineoplastic Agents

KW - Drug Administration Schedule

KW - Erythropoiesis

KW - Erythropoietin

KW - Hematinics

KW - Humans

KW - Neoplasms

KW - Recombinant Proteins

KW - Treatment Outcome

U2 - 10.1111/j.1365-2362.2005.01527.x

DO - 10.1111/j.1365-2362.2005.01527.x

M3 - SCORING: Journal article

C2 - 16281955

VL - 35 Suppl 3

SP - 26

EP - 31

JO - EUR J CLIN INVEST

JF - EUR J CLIN INVEST

SN - 0014-2972

ER -